JQEZ5

News alerts, weekly reports and conference planners

Company:

Dana-Farber Cancer Institute

Drug class:

EZH2 inhibitor

Related drugs:

EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	JQEZ5 Sensitive: D – Preclinical JQEZ5 Sensitive : D	JQEZ5 Sensitive: D – Preclinical JQEZ5 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	dabrafenib + JQEZ5 Sensitive: D – Preclinical dabrafenib + JQEZ5 Sensitive : D	dabrafenib + JQEZ5 Sensitive: D – Preclinical dabrafenib + JQEZ5 Sensitive : D

Associations
(2)